Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

Johanne Silvain; Anne Bellemain-Appaix; Olivier Barthélémy; Farzin Beygui; Jean‐Philippe Collet; Gilles Montalescot

doi:10.1161/circinterventions.109.910406

February 1, 2011Circulation Cardiovascular InterventionsOpen Access

Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does high-dose clopidogrel and high-dose aspirin improve outcomes in patients with NSTE-ACS compared to standard doses?

Structured PICO

Does high-dose clopidogrel and high-dose aspirin improve outcomes in patients with NSTE-ACS compared to standard doses?

P

Population

Patients with non-ST-elevation acute coronary syndrome (NSTE-ACS)

I

Intervention

High-dose clopidogrel (600-mg loading dose / 150-mg maintenance dose) and high-dose aspirin (300 to 325 mg)

C

Comparator

Standard-dose clopidogrel (300-mg loading dose / 75-mg maintenance dose) and low-dose aspirin (75 to 100 mg)

O

Outcome

Ischemic events

Implication

This review evaluates the implications of the CURRENT-OASIS 7 trial for optimizing dual antiplatelet therapy dosing in patients with NSTE-ACS.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Silvain et al. (2011) studied this question.

synapsesocial.com/papers/6a8800fc8dfe8b7ec5a53234 https://doi.org/10.1161/circinterventions.109.910406

View Full Paper

Ask AI

Bookmark

Share

Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading